facebook

Alchemy Ascent

Scheme Rating

IME Scheme Rating

The Scheme does not meet our selection criteria at this time

Investment Option: We would advise investors to wait for the scheme to mature (5 years+), before deploying capital into this strategy.

IME Strategy Rating

Quant-Algorithm based Approach: Alchemy Ascent follows a quant-algorithm approach towards stock selection. This is a departure from Alchemy’s past focus as a fundamental active stock picker, and the value of their quant algorithm is yet to be proven.

PMS Scheme Ratings are driven by IME’s Proprietary Scheme Rating Methodology, which takes into account our ratings of the Scheme’s investment strategy, its maturity, the investment team, and our separate rating on the AMC that runs this particular scheme. Our views on each of these individual criteria are available via the IME RMS – which you can view by reaching out to one of our relationship managers (using either the live chat or book appointment feature on this site).

IME View on Alchemy Ascent

Type: Flexi Cap | Quant | AUM (626.1 cr) | Inc Date (3 Sep 2019)

Alchemy Ascent- Investment Strategy

Quant based strategy

Alchemy Ascent follows a quant-based investment strategy, the takes an unbiased approach towards each stock by allowing data to filter out emotions of greed and fear. Various parameters are fed into the model including quality filters, negative marking for unfavorable BS ratios, financial/fundamental parameters, and more, all of which are combined to get an individual score for each stock that changes on a daily basis.

Trailing Performance

1yr 3yr 5yr Since Inception
Alchemy Ascent 49.6 20.2 24.3 24.3
S&P BSE 500 TRI 41.1 18.4 22.4 23
Alpha over Broad Mkt BM 8.5 1.8 1.9 1.3
Nifty 500 40.2 17.2 21
Alpha over Category BM 9.4 3 3.3

Performance as of: 30-Sep-24 | Inception Date: 03-Sep-19

Fund Managers

Vikas Kumar | 4-star rated FM

Fund Manager | 24 yrs Experience

Past Experience: Dalal & Broacha, Reliance Capital

Vikas has over 19 years of equity market experience, in the fields of equity research, private client fund management and strategy in the sell-side. He specialises in data-based quantitative algorithms.

Fee Structure

Fee StructureFee
Fixed Fee Structure2.5
Variable Fee Structures1.5% fixed + 15% above 10% hurdle
Exit Fees1yr(1%)

AMC

AMC: Alchemy PMS (click link for detailed AMC review)

Not a top recommendation (at this time) due to weak recent performance: Backed by solid founders, a CIO that is a co-founder and well-respected investor and a long track record of identifying interesting bottom-up investment opportunities, Alchemy has all the ingredients for a successful PMS business. However, their performance has been very sub-par in recent years, and it is this underperformance that is the primary reason behind Alchemy not being a 5 or 4-star rated PMS.

AMC Rating

3 of 5 stars

AMC Pedigree

4 of 5 stars

AMC Size

4 of 5 stars

Team Pedigree

5 of 5 stars

Inv Philosophy

3 of 5 stars

Performance

3 of 5 stars

Free 30-Day Trial of the IME RMS

Details shared above, are only a short-snapshot of the more detailed analysis that resides in IME’s Proprietary RMS (Research Management Solution).

The IME RMS is the first tool ever, to give investors direct access to the insights of the central research team. Investors gain direct access to our ratings, rating rationales & analysis across thousands of funds (MFs, PMSs, AIFs, Global funds), asset classes, categories & more.

 Learn More

IME RMS Demo

Register 30-Day Trial

Note: PMS AMC & Scheme Reviews and Ratings are based on IME Capital’s Proprietary Review and Rating Methodology (read more here: AMC Rating & Scheme Ratings). These reflect the unbiased views of our central research team, based on our assessment of the investment value of these PMS/AIF strategies for our investors. We follow a highly stringent rating-criteria, where approximately 50% of PMS AMC’s & strategies would be rated 2-star or below (this is not meant to indicate that these funds are not investment-worthy, but that they do not currently fulfill the requirements we focus on for recommending funds to our investors — based on our internal views on the merit of the AMC/strategy relative to peers). Reviews & Ratings are primarily based on research of publicly available information (SEBI disclosures, PMS websites, PMS-aggregation platforms, webinar recording, media interviews etc.) and no explicit consent is required from AMCs for the same. While we endeavour to do further due-diligence via direct interactions with the investment teams of AMCs, this is typically restricted to AMC’s that meet our foundational fund selection criteria (reviews on lower-rated AMCs are often based solely on publicly available information). The views reflected in our Reviews & Ratings, are our independent views and may not be shared by the AMC’s and the investment teams. Please read detailed disclaimer for more.

CONNECT WITH US

Use our Live Chat
Book 15-min Introductory Call
WhatsApp us @ +91 96320 07774

IME Capital Pvt. Ltd. is a research-first investments firm. We aim to disrupt the wealth management industry, by shrinking the gap in investment insights between central research teams & RMs/Clients. 

Products
Solutions
Disclaimer MF/PMS/AIF/Direct Equities are all subject to market risks. Please read the scheme information and other related documents carefully prior to investing. Past performance is not indicative of future returns. Please consider your specific investment requirements before choosing a fund or designing a portfolio that suits your needs. Market & other data on this site has been sourced from what are considered to be reliable sources. All views shared (product ratings, views on individual securities etc.) are the proprietary property of IME Capital and cannot be used in any form without explicit written consent. IME Capital Pvt. Ltd. makes no warranties or representations, express or implied, on products offered through the platform (and that of our partners) or on the correctness of data & views shared. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Detailed Disclaimer © 2021 All rights reserved | ARN No: ARN-182445